Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novartis AG

ChrysCapital acquires controlling 70.68% stake in Novartis' India listed unit in first majority pharma investment

ChrysCapital has acquired a controlling interest in Novartis India Limited, representing its inaugural investment in India's pharmaceutical landscape. Following this acquisition, the company is set to unveil a fresh name and corporate identity. Vikas Gupta has been appointed as the new CEO, with plans to create a competitive branded generics…

The Economic Times

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).

Benzinga

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).

Benzinga

Stocks Settle Higher on Hopes of Accelerated Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.33%. September E-mini S&P futures (ESU25 ) rose +0.28%, and September E-mini Nasdaq futures...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stocks Turn Mixed as US Job Growth Less Than Previously Stated

The S&P 500 Index ($SPX ) (SPY ) today is up +0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.08%. September E-mini S&P futures (ESU25 ) are down -0.08%, and September E-mini Nasdaq futures...

Barchart

Stocks Edge Higher on Expectations for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.19%. September E-mini S&P futures (ESU25 ) are up +0.07%, and September E-mini Nasdaq futures...

Barchart

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Benzinga

Novartis Raises Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback (CORRECTED)

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

Benzinga

3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical stocks Pfizer (PFE), AstraZeneca (AZN), and Novartis (NVS), which are transforming medicine with AI-powered drug discovery, could be ideal portfolio additions. Continue reading.

StockNews.com

3 Gene Therapy Stocks With Game-Changing Potential

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, investing in gene therapy stocks like Pfizer (PFE), Sanofi (SNY), and Novartis AG (NVS) could be beneficial. Read on….

StockNews.com

PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 European Stocks to Watch as the EU Economy Strengthens

With inflation dropping to 2.2% in August 2024 and the potential for further interest rate cuts on the horizon, European markets could become more attractive as growth picks up. Thus, one could consider keeping an eye on fundamentally sound European stocks like Novartis (NVS), Unilever (UL), and Siemens Aktiengesellschaft (SIEGY).…

StockNews.com

3 High-Dividend Pharma Blue Chips That Are on Sale Right Now

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the market. Amid this backdrop, it could be wise to scoop up the shares of fundamentally sound pharma stocks like AbbVie (ABBV), Novartis (NVS), and Pfizer (PFE), which are not just…

StockNews.com

3 European Stocks to Buy as the Continent’s Economy Recovers

As Europe navigates a complex landscape of slowing inflation, stable employment, and modest GDP growth, it may be an opportune time for investors to consider investing in quality stocks like Novo Nordisk (NVO), SAP SE (SAP), and Novartis (NVS), which are poised to capitalize on the continent’s recovery. Read on….

Barchart

Chart of the Day: Novartis - Take Another Look

The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Pharma Titans Making Waves in Wall Street

The pharma industry is well-positioned to remain buoyed, owing to the rise in chronic diseases, a growing elderly population, and the integration of advanced technologies. Given this backdrop, quality pharma stocks Bristol-Myers Squibb Company (BMY), Johnson & Johnson (JNJ), Novartis AG (NVS), and Merck & Co. (MRK), making waves in…

StockNews.com

4 Sky-Rocketing Pharma Stocks to Watch

The pharmaceutical industry is experiencing significant growth due to the rising demand for quality healthcare and high-quality drugs. This surge is further supported by the rapid growth in the global elderly population and the increase in chronic illnesses. Therefore, investors could consider adding pharma stocks Spero Therapeutics (SPRO), Wave Life…

StockNews.com

Top 3 Pharma Stocks With Bullish Momentum

The pharmaceutical industry’s future appears increasingly optimistic, encouraged by surging healthcare spending due to the rise of chronic and rare disease incidences and an expanding elderly population. The encouraging prognosis of the industry is further bolstered by unwavering ventures into research and development structures and technological advancements. Given this backdrop,…

StockNews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

3 Pharma Powerhouses to Watch Closely

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Therefore, it could be wise to keep an eye on top pharma stocks, Roche Holding (RHHBY), Novartis (NVS) and AbbVie (ABBV). Continue reading.

StockNews.com

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Dow Jones Industrials

316 stories

Pfizer Inc

314 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.